<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        54-370-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        JALRA 50 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VILDAGLIPTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        45.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Siegfried Barbera, S.L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Siegfried Barbera, S.L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each JALRA tablet contains 50 mg of the active substance vildagliptin.</p><p>JALRA is a medicine used to treat patients with type 2 diabetes whose condition cannot be controlled by diet and exercise alone. It helps to control the level of sugar in the blood. Such medicines are&nbsp; known&nbsp; as&nbsp; oral&nbsp; antidiabetics. Type 2 diabetes develops if the body does not produce enough insulin or where the insulin that your body makes does not work as well as it should. It can also develop if the body produces too much glucagon.</p><p>Insulin is a substance which helps to lower the level of sugar in your blood, especially after meals. Glucagon is another substance which triggers the production of sugar by the liver, causing the blood sugar to rise. The pancreas makes both of these substances.</p><p>JALRA works by making the pancreas produce insulin and less glucagon. JALRA helps to control the blood sugar level.</p><p>Your doctor will prescribe JALRA either alone or in combination with other antidiabetics depending on your condition.</p><p>It is important that you continue to follow the diet and/or exercise advised for you whilst you are on treatment with JALRA.</p><p>Ask your doctor if you have any questions about why this medicine has been prescribed for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all instructions given to you by your doctor or<br />pharmacist carefully even if they differ from the information<br />contained in this leaflet.<br /><strong>Do not take JALRA</strong><br />If you are allergic )hypersensitive( to vildagliptin or any of<br />the other ingredients of JALRA.<br /><strong>Take special care with JALRA</strong><br />If you are pregnant or plan to become pregnant.<br />If you are breast-feeding.<br />If you have kidney problems.<br />If you have liver problems.<br />If you are suffering from heart failure, your doctor will<br />decide whether or not to prescribe JALRA depending on the<br />degree of your condition.<br />JALRA is not a substitute for insulin. You should therefore<br />neither receive JALRA for the treatment of type 1 diabetes<br />)i.E. Your body does not produce insulin at all( nor for the<br />treatment of a condition called diabetic ketoacidosis.<br />If any of these apply to you, tell your doctor before you take<br />JALRA.<br /><strong>Monitoring your JALRA treatment</strong><br />Your doctor should ensure that the following tests are<br />performed:<br />Blood and urine tested for sugar regularly<br />Check how your liver functions:<br />At start of treatment<br />Every 3 months during the first year of treatment and<br />regularly thereafter<br />If your doctor told you to stop your treatment with JALRA<br />because of liver problems you should never start taking<br />JALRA again<br /><strong>Taking JALRA with food and drink</strong><br />JALRA can be taken with or without a meal.<br /><strong>JALRA and older people</strong><br />JALRA can be used by elderly patients.<br /><strong>JALRA and children</strong><br />There is no information available on the use of JALRA in<br />children )less than 18 years(. The use of JALRA in these<br />patients is therefore not recommended.<br /><strong>Pregnant women</strong><br />Tell your doctor if you are, you think you might be or are<br />planning to become pregnant. Your doctor will discuss with<br />you the potential risk of taking JALRA during pregnancy.<br />Ask your doctor or pharmacist for advice before taking any<br />medicine during pregnancy.<br /><strong>Breast-feeding mothers</strong><br />Do not breast-feed during treatment with JALRA.<br />Ask your doctor or pharmacist for advice before taking any<br />medicine while you are breast-feeding.<br /><strong>Driving and using machines</strong><br />Patients experiencing dizziness should avoid driving vehicles<br />or using machines.<br /><strong>Important information about some of the ingredients of<br />JALRA</strong><br />JALRA contains an ingredient called lactose )milk sugar(. If<br />you have severe lactose intolerance, galactose intolerance,<br />or glucose-galactose malabsorption, tell you doctor before<br />taking JALRA.<br /><strong>Jalra contains sodium</strong><br />This medicine contains less than 1 mmol sodium )23 mg( per<br />tablet, that is to say essentially &lsquo;sodium free&rsquo;.<br /><strong>Taking other medicines</strong><br />Tell your doctor or pharmacist if you are taking or have<br />recently taken any other medicines. Remember also those<br />not prescribed by a doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all instructions given to you by your doctor and<br />pharmacist carefully even if they differ from the ones given<br />in this leaflet. Do not take more JALRA than your doctor has<br />prescribed.<br /><strong>How much to take</strong><br />Your doctor will tell you exactly how many tablets of JALRA<br />to take.<br />The usual dose of JALRA is 50 mg or 100 mg a day. The 50 mg<br />dose should be taken as 50 mg once a day )morning(. The 100<br />mg dose should be taken as 50 mg twice a day )morning and<br />evening(. Depending on how you respond to the treatment,<br />your doctor may suggest a higher or lower dose.<br />Your doctor will prescribe JALRA either alone or in combination<br />with other antidiabetics depending on your condition.<br /><strong>When and how to take JALRA</strong><br />JALRA should be taken in the morning )50 mg once a day( or<br />in the morning and in the evening )50 mg twice a day(.<br />The tablets should be swallowed whole with a glass of water.<br /><strong>How long to take JALRA</strong><br />continue taking JALRA every day for as long as your doctor<br />tells you. You may have to stay on this treatment for a<br />long period of time. Your doctor will regularly monitor your<br />condition to check that the treatment is having the desired<br />effect.<br />If your doctor told you to stop your treatment with JALRA<br />because of liver problems you should never start taking<br />JALRA again.<br />If you have questions about how long to take JALRA, talk to<br />your doctor.<br /><strong>If you forget to take JALRA</strong><br />If you forget to take JALRA, take it as soon as you remember.<br />Then take your next dose at the usual time. However, if it is<br />almost time for your next dose, skip the dose you missed.<br />Do not take a double dose to make up for the forgotten tablet.<br /><strong>If you take more JALRA than you should</strong><br />If you have accidentally taken too many JALRA tablets, or<br />if someone else has taken your medicine, talk to a doctor<br />straight away. You may need medical attention. Show the<br />doctor the pack if possible.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>JALRA can have some side effects in some people.<br />Some patients have experienced the following side effects<br />whilst taking JALRA alone or in combination with another<br />antidiabetic medication:<br /><strong>Some symptoms need immediate medical attention:</strong><br />You should <strong>stop taking JALRA and see your doctor</strong><br />immediately if you experience the following symptoms:<br />Swollen face, tongue or throat, difficulty swallowing,<br />difficulty breathing, sudden onset of rash or hives )symptoms<br />of severe allergic reaction called &#39;angioedema&#39;(.<br />Yellow skin and eyes, nausea, loss of appetite, dark-colored<br />urine )possible symptoms of liver problems(.<br />Severe upper stomach pain )possible sign of inflamed<br />pancreas(.<br /><strong>Other side effects<br />Some patients have had the following side effects while<br />taking Jalra:<br />Very common </strong>)may affect more than 1 in 10 people(: sore<br />throat, runny nose, fever.<br /><strong>Common </strong>)may affect up to 1 in 10 people(: itchy rash,<br />trembling, headache, dizziness, muscle pain, joint pain,<br />constipation, swollen hands, ankles or feet )oedema(,<br />excessive sweating, vomiting, pain in and around the stomach<br />)abdominal pain(, diarrhoea, heartburn, nausea )feeling sick(,<br />blurred vision.<br /><strong>Uncommon </strong>)may affect up to 1 in 100 people(: weight<br />increase, chills, weakness, sexual dysfunction, low blood<br />glucose, flatulence.<br /><strong>Rare </strong>)may affect up to 1 in 1 000 people(: inflammation of<br />the pancreas.<br /><strong>Since this product has been marketed, the following<br />side effects have also been reported:<br />Frequency not know</strong>n )cannot be estimated from the<br />available data(: localised peeling of skin or blisters, blood<br />vessel inflammation )vasculitis( which may result in skin rash<br />or pointed, flat, red, round spots under the skin&#39;s surface or<br />bruising.<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist<br />or nurse. This includes any possible side effects not listed in<br />this leaflet.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use after the expiry date shown on the box.<br />Store in the original package.<br />Do not use any JALRA pack that is damaged or shows signs<br />of tampering.<br />Do not store JALRA above 30&deg;c.<br />Keep out of the reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance of JALRA is vildagliptin.<br />The other ingredients are: lactose anhydrous, microcrystalline<br />cellulose, sodium starch glycolate, magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Available in packs containing 28 or 56 tablets
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals</p><p>Saudi Arabian Japanese pharmaceutical company limited</p><p>Jeddah - Saudi Arabia</p><p>Under License from Novartis Pharma AG, Switzerland</p><p><strong>-To report any side effect (s)<br />.Saudi Arabia</strong><br />- Tlie National Pfiarmacovigilance Centre (NPC):<br />- SFDA Call Center:19999<br />- E-mail: npcdrug@sfdagov.sa</p><table><tbody><tr><td>- Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td><strong>Other GCC States,other countries:</strong></td></tr></tbody></table><table><tbody><tr><td>- Please contact the relevant competent authority.</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتـوي القـرص الواحـد مـن جـالرا علـى 50ملـج مـن المـادة الفعالـة<br />فیلداجليبتيــن<br />جــالرا هــو دواء يســتعمل لــعلاج المرضــي الذيــن لديهــم النــوع ۲<br />مــن مــرض الســكر والذيــن لا يمكــن الســيطرة علــى مرضهــم بالنظــام<br />الغذائـي أو بالرياضـة فقـط، وهـو يسـاعد فـي السـيطرة علـى مسـتوى<br />السـكر فـي الـدم. هـذه الأدويـة تسـمى مضـادات مـرض السـكر التـي<br />تؤخــذ بالفــم<br />ينشـأ النـوع ۲مـن مـرض السـكر عندمـا لا ينتـج جسـمك القـدر الكافـي<br />مــن الأنســولين أو عندمــا يكــون الأنســولين الــذي ينتجــه جســمك غيــر<br />فعــال بالقــدر الكافــي، وهــو قــد يحــدث أي ًضــا إذا كان الجســم ينتــج<br />جلوكاجــون بأكـــر ممــا ينبغــي<br />الأنسـولين هـو مـادة تسـاعد فـي خفـض مسـتوى السـكر فـي دمـك،<br />لا سـيما بعـد الأكل، الجلوكاجـون هـو مـادة أخـرى تحفـز إنتـاج السـكر<br />بواسـطة الكبـد، ممـا يـؤدي إلـى ارتفـاع السـكر الـدم. البنكريـاس هـو<br />الـذي ينتـج كلتـا هاتيـن المادتيـن<br />يعمــل جــالرا بــأن يجعــل البنكريــاس ينتــج أنســولين أكـــر وجلوكاجــون<br />أقــل يســاعد جــالرا فــي الســيطرة علــى مســتوى الســكر فــي الــدم<br />إن طبيبــك ســيصف لــك جــالرا إمــا بمفــرده أو بالاشــتراك مــع أدويــة<br />أخــرى مضــادة لمرضــى الســكر وفقــا لحالتــك<br />مـن المهـم أن تسـتمر اتبـاع النظـام الغذائـي و/أو الرياضـة الموصوفـة<br />للـك أتـاء علاجـك بواسـطة جـالرا<br />اسـال طبيبـك إذا كانـت لديـك أي أسـئلة عـن سـبب وصـف هـذا الـدواء<br />لك<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">التـزم بجميـع تعليمـات طبيبـك أو الصيدلـي بـكل دقـة، حتـى إذا كانـت<br />مختلفـة عـن المعلومـات المذكـورة فـي هـذه النشـرة<br /><strong>لا تستعمل جالرا</strong><br />إذا كانـت لديـك أرجيـة (حساسـية مفرطـة) تجـاه فیلداجليبتيـن أو تجـاه<br />أي مـن المكونـات الأخـرى فـي جالـرا.<br /><strong>يجب توخي الحذر الخاص مع جالرا</strong><br />إذا كنت حاملا أو تخططين للحمل.<br />إذا كنت مرضعة<br />إذا كانت لديك مشاكل في الكلى.<br />إذا كانت لديك مشاكل في الكبد<br />إذا كنـت تعانـي مـن الفشـل القلبـي، سـوف يقـرر طبيبـك مـا إذا كان<br />مـن الممكـن أن يصـف لـكل جالـرا أم لا بنـاء علـى درجـة حالتـك.<br />جالـرا ليـس بديـلا للأنسـولين، لذلـك يجـب عـدم اسـتعمال جالـرا سـواء<br />لعــلاج النــوع ۱مــن مــرض الســكر (أي أن جســمك لا ينتــج الأنســولين<br />علـى الإطـلاق) أو لعـلاج حالـة تسـمى الحمـاض الكيتونـي الناتـج عـن<br />مـرض السـكر.<br />إذا انطبـق علـى أي مـن الأمـور المذكـورة اعلاه، أخبـر طبيبـك قبـل أن<br />تسـتعمل جـالرا<br /><strong>المراقبة أثناء علاجك بواسطة جالرا</strong><br />سوف يحرص طبيبك على إجراء الاختبارات التالية:<br />قياس السكر في الدم والبول بصفة منتظمة<br />قياس وظائف كبدك:<br />- عند بدء العلاج<br />- کل ۳شـهور خـلال السـنة الأولـى مـن العـلاج وبصفـة دوريـة بعـد<br />ذلـك<br />إذا نصحــك طبيبــك بــأن توقــف اســتعمال جــالرا بســبب مشــاكل فــي<br />الكبــد يجــب ألا تبــدأ علــى الإطلاق فــي اســتعمال جــالرا مــرة أخــرى<br /><strong>استعمال جالرا مع الطعام والشراب</strong><br />يمكنك تناول جالرا مع الطعام أو بدونه.<br /><strong>جالرا في الأشخاص المسنين</strong><br />يمكن استعمال جالرا في المرضى المسنين.<br /><strong>جالرا في الأطفال</strong><br />لا توجـد معلومـات بشـأن اسـتعمال جـالرا فـي الأطفـال (تحت 18سـنة<br />مـن العمـر،) لذلـك لا يوصـى باسـتعمال جـالرا فـي هـؤلاء المرضى<br /><strong>النساء الحوامل</strong><br />أخبــري طبيبــك إذا كانــت حــاملا، أو إذا اشــتبهت فــي أنــك حامــل أو<br />إذا كنــت تخططيــن للحمــل، فــإن طبيبــك ســيناقش معــك المخاطــر<br />الممكنــة التــي قــد تترتــب علــى إعطائــك جــالرا أثنــاء الحمــل<br />استشيري طبيبك أو الصيدلي قبل أخذ أي دواء أثناء الحمل.<br /><strong>الأمهات المرضعات</strong><br />امتنعي عن الإرضاع أثناء استعمال جالرا<br />استشيري طبيبك أو الصيدلي قبل أخذ أي دواء أثناء الإرضاع.<br /><strong>قيادة السيارة وتشغيل الآلات</strong><br />يجـب علـى المرضـى الذيـن يشـعرون بدوخـة أن يتجنبـوا قيـادة السـيارة<br />أو تشـغيل الآلات<br /><strong>معلومات هامة عن بعض المكونات في جالرا</strong><br />يحتــوي جــالرا علــى لاكتــوز (ســكر الحليــب.) إذا كانــت لديــك حالــة<br />شـديدة مـن عـدم تحمـل اللاكتـوز، أو عـدم تحمـل الجالاكتـوز، أو سـوء<br />امتصــاص الجلوكــوز والجالاكتــوز، أخبــر طبيبــك قبــل أن تأخــذ جــالرا<br /><strong>یحتوي جالرا على الصودیوم</strong><br />یحتــوي جــالرا علــى أقــل مــن ۱ملیمــول صودیــوم ( ۲۳ملــغ) لــكل<br />قــرص، وھــذا یعنــي بشــكل أساســي &quot;خــا ٍل مــن الصودیــوم&quot;<br /><strong>استعمال أدوية أخرى</strong><br />أخبــر طبيبــك أو الصيدلــي إذا كنــت تســتعمل حاليــا أو إذا كنــت قــد<br />اسـتعملت منـذ فتـرة قصيـرة أي أدويـة أخـرى، تذكـر أيضـا الأدويـة غيـر<br />الموصوفــة بواســطة طبيــب</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">التــزم بــكل دقــة بالتعليمــات التــي أعطاهــا لــك طبيبــك والصيدلــي<br />حتـى إذا كانـت مختلفـة عـن التعليمـات المذكـورة فـي هـذه النشـرة.<br />لا تأخــذ جــالرا بأكـــر مــن الجرعــة التــي وصفهــا لــك طبيبــك<br /><strong>ماهي الكمية التي ينبغي أن تأخذها</strong><br />سـوف يخبـر طبيبـك كـم عـدد الأقراص بالضبـط التـي يجـب أن تأخذهـا<br />مـن جـالرا<br />الجرعــة المعتــادة مــن جــالرا هــي 50ملــج أو ۱۰۰ملــج فــي اليــوم.<br />تؤخــذ الجرعــة 50ملــج فــي شــكل 50ملــج مــرة واحــدة فــي اليــوم<br />(فــي الصبــاح)<br />تؤخـذ الجرعـة ۱۰۰ملـج فـي شـكل 50ملـج مرتيـن فـي اليـوم (فـي<br />الصبــاح والمســاء،) وفقــا لمــدى اســتجابتك للــعلاج، قــد يقــترح عليــك<br />طبيبــك جرعــة أكبــر أو أقــل<br />إن طبيبــك ســيصف لــك جــالرا إمــا بمفــرده أو بالاشــتراك مــع أدويــة<br />أخــرى مضــادا لمــرض الســكر وفقـ ً ـا لحالتــك<br /><strong>متى وكيف ينبغي أن تأخذ جالرا</strong><br />يؤخــذ جــالرا فــي الصبــاح ( 50ملــج مــرة واحــدة فــي اليــوم) أو فــي<br />الصبــاح والمســاء ( 50ملــج مرتيــ ً ن يوميــا)<br />تبلع الأقراص صحيحة مع كوب من الماء.<br /><strong>ما هي مدة استعمال جالرا</strong><br />اســتمر فــي اســتعمال جــالرا يوميــا للمــدة التــي يحددهــا طبيبــك. قــد<br />تحتــاج أن تســتمر علــى هــذا الــعلاج لفتــرة زمنيــة طويلــة، ســيراقب<br />طبيبــك حالتــك بصفــة منتظمــة للتأكــد مــن أن الــعلاج يحقــق التأثيــر<br />المطلــوب<br />إذا نصحــك طبيبــك بــأن توقــف اســتعمال جــالرا بســبب مشــاكل فــي<br />الكبــد يجــب ألا تبــدأ علــى الإطلاق فــي اســتعمال جــالرا مــرة أخــرى<br />إذا كانت لديك أسئلة عن مدة استعمال جالرا، تحدث مع طبيبك.<br /><strong>إذا نسيت أن تأخذ جالرا</strong><br />إذا نســيت أن تأخــذ جــالرا خــذه بمجــرد أن تتذكــره، ثــم خــذ جرعتــك<br />التاليـة فـي موعدهـا المعتـاد، ولكـن إذا كان موعـد جرعتـك التاليـة قـد<br />اقتــرب، تغاضــى عــن الجرعــة المنســية<br />لا تأخذ جرعة مضاعفة للتعويض عن القرص المنسي<br /><strong>إذا أخذت جالرا بأكثر مما ينبغي</strong><br />إذا أخـذت علـى سبيـل الخطـأ عـددا مـن أقراص جـالرا بأكــر ممـا ينبغـي،<br />أو إذا أخــذ أي شــخص آخــر مــن دوائــك علــى سبيــل الخطــأ، اتصــل<br />بطبيبـك فـورا. فإنـك قـد تحتـاج إلـى رعايـة طبيـة. إن أمكـن خـذ معـك<br />العبـوة لكـي يراهـا طبيبـك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شـأنه شـأن جميـع الأدويـة قـد يـؤدي جـالرا إلـى حـدوث بعـض الآثـار<br />الجانبيــة فــي بعــض الأشــخاص ســواء بمفــرده أو بالاشــتراك مــع دواء<br />آخـر مضـاد لمـرض السـكر<br /><strong>بعض الأعراض تحتاج إلى رعاية طبية عاجلة:</strong><br />يجـب أن <strong>توقـف اسـتعمال جـالرا وأن تذهـب فـورا إلـى الطبيـب </strong>إذا<br />حدثـت لديـك الأمراض التاليـة<br />تــورم الوجــه، أو اللســان، أو الحلــق. صعوبــة فــي البلــع، صعوبــة<br />التنفــس، حــدوث مفاجــئ لطفــح أو أرتيكاريــا (أعراض حــدوث تفاعــل<br />أرجــي شــديد يســمى &quot;الوذمــة الوعائيــة)&quot;<br />اصـفرار الجلـد والعينيـن، غـيـان، فقـدان الشـهية، بـول داكـن (أعراض<br />قـد تـدل علـى مشـاكل فـي الكبـد)<br />ألــم شــديد فــي أعلــى البطــن (علامــات قــد تــدل علــى التهــاب<br />البنكريــاس)<br /><strong>آثار جانبية أخرى<br />عانـى بعـض المرضـى مـن الآثـار الجانبيـة التاليـة أثنـاء تنـاول عقـار<br />جالرا:<br />شــائعة جــ ًدا </strong>(قــد تصيــب أكـــر مــن شــخص واحــد ( )۱مــن كل ۱۰<br />أشــخاص:) التهــاب الحلــق، ســيلان الأنــف، الحمــى<br /><strong>شــائعة </strong>(قــد تؤثــر علــى مــا يصــل إلــى شــخص واحــد ( )۱مــن كل ۱۰<br />أشـخاص:) طفـح جلـدي مصحـوب بحكـة، ارتعـاش، صـداع، دوخـة، ألـم<br />فـي العـضلات، ألـم فـي المفاصـل، إمسـاك، تـورم اليديـن، أو الكاحليـن<br />ّ أو القدميــن (وذمــة،) فــرط التــعرّق، قــيء، ألــم فــي المعــدة وحولهــا<br />(ألــم فــي البطــن،) إســهال، حرقــة فــي المعــدة، غـيــان (الشــعور<br />بالمــرض،) تشــوش الرؤيــة<br /><strong>غيـر شـائعة </strong>(قـد ُتصيـب مـا يصـل إلـى شـخص واحـد ( )۱مـن كل ۱۰۰<br />شــخص:) زيــادة الــوزن، قشــعريرة، ضعــف، اخــتلال الوظيفــة الجنســية،<br />انخفـاض الجلوكـوز فـي الـدم، انتفـاخ البطـن<br /><strong>نـادرة </strong>(قـد ُتصيـب مـا يصـل إلـى شـخص واحـد ( )۱مـن بيـن كل ۱۰۰۰<br />شـخص:) التهـاب البنكريـاس<br /><strong>منــذ تســويق هــذا المنتــج، تــم الإبلاغ أيضــا عــن الآثــار الجانبيــة<br />التاليــة:<br />معـدل التـكرار غيـر مـعروف </strong>(لا يمكـن تقديـره مـن البيانـات المتاحـة:)<br />تقشــر موضعــي للجلــد أو بـــور، التهــاب الأوعيــة الدمويــة (التهــاب<br />وعائــي) الــذي قــد يــؤدي إلــى طفــح جلــدي أو بقــع مدببــة، أو<br />مســطحة، أو حــمراء، أو مســتديرة تحــت ســطح الجلــد أو كدمــات<br /><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا أ ًصبــ َت بأيــة آثــار جانبيــة، فتحــدث إلــى الطبيــب المتابــع لــك أو<br />الصيدلــي أو الممرضــة. يشــمل ھــذا أيــة آثــار جانبيــة محتملــة غيــر<br />مذكــورة فــي هــذه النشــرة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا ينبغــي اســتعماله بعــد تاريــخ انتهــاء الصلاحيــة المذكــور علــى<br />العلبـة<br />يحفظ في عبوته الأصلية.<br />لا تســتعمل أي عبــوة مــن جــالرا إذا كانــت تالفــة أو تظهــر عليهــا<br />علامــات العبــث<br />يحفظ جالرا في درجة حرارة لا تزيد عن ٣۰ درجة مئوية.<br />يحفظ بعيد ًا عن متناول ومرأى الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة في جالرا هي فیلداجليبتين.<br /><strong>المكونات الأخرى هي:</strong><br />لاكتــوز لامائــي، ســيليلوز دقيــق التبلــور، صوديــوم نشــا جلايكــولات،<br />ســتيارات ماغنســيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>متوفر في عبوات تحتوي على 28 قرصا او على 56 قرصا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مصنع ساجا للصناعات الدوائية<br />الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة<br />جدة - المملكة العربية السعودية<br />بترخيص من شركة نوفارتس فارما آيه جى ، سويسرا<br /><br /><strong>للإبلاغ عن أية آثار جانبية<br />&bull; المملكة العربية السعودية</strong><br />- المركز الوطني للتيقظ والسلامة الدوائية<br />- مركز اتصال هيئة الغذاء والدواء : 19999<br />npc.drug@sfda.gov.sa :- البريد الإلكتروني<br />https://ade.sfda.gov.sa :- الموقع الإلكتروني<br /><strong>&bull; </strong><strong>دول الخليج الأخرى/ الدول الأخرى</strong><br />- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة<br />إن هذا دواء<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اكتوبر/ 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JALRA 50mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 50mg of vildagliptin.
Excipient with known effect: Each tablet contains 47.82 mg lactose (anhydrous).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
White to light yellowish, round (8mm diameter), flat-faced, bevelled-edge tablet.
One side is debossed with “NVR”, and the other side with “FB”.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults: As monotherapy</p><p>&minus;&nbsp; in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.</p><p>As dual oral therapy in combination with</p><p>&minus;&nbsp; metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin,</p><p>&minus;&nbsp; a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance,</p><p>&minus;&nbsp; a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.</p><p>As triple oral therapy in combination with</p><p>&minus;&nbsp; a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.</p><p>Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet</p><p>and exercise plus a stable dose of insulin do not provide adequate glycaemic control.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Adults</u></em></p><p>When used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in combination with metformin and a sulphonylurea, or in combination with insulin (with or without metformin), the recommended daily dose of vildagliptin is 100 mg, administered as one dose of 50 mg in the morning and one dose of 50 mg in the evening.</p><p>&nbsp;</p><p>When used in dual combination with a sulphonylurea, the recommended dose of vildagliptin is 50 mg once daily administered in the morning. In this patient population, vildagliptin 100 mg daily was no more effective than vildagliptin 50 mg once daily.</p><p>&nbsp;</p><p>When used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.</p><p>&nbsp;</p><p>Doses higher than 100 mg are not recommended.</p><p>&nbsp;</p><p>If a dose of JALRA is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.</p><p>&nbsp;</p><p>The safety and efficacy of vildagliptin as triple oral therapy in combination with metformin and a thiazolidinedione have not been established.</p><p>&nbsp;</p><p><em><u>Additional information on special populations</u> Elderly (&ge; 65 years)</em></p><p>No dose adjustments are necessary in elderly patients (see also sections 5.1 and 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required in patients with mild renal impairment (creatinine clearance &ge; 50 ml/min). In patients with moderate or severe renal impairment or with end-stage renal disease (ESRD), the recommended dose of JALRA is 50 mg once daily (see also sections 4.4, 5.1 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>JALRA should not be used in patients with hepatic impairment, including patients with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3x the upper limit of normal (ULN) (see also sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>JALRA is not recommended for use in children and adolescents (&lt; 18 years). The safety and efficacy of JALRA in children and adolescents (&lt; 18 years) have not been established. No data are available (see also section 5.1).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral use</p><p>JALRA can be administered with or without a meal (see also section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section
6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>&nbsp;</p><p>JALRA is not a substitute for insulin in insulin-requiring patients. JALRA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>There is limited experience in patients with ESRD on haemodialysis. Therefore JALRA should be used with caution in these patients (see also sections 4.2, 5.1 and 5.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>JALRA should not be used in patients with hepatic impairment, including patients with pre-treatment ALT or AST &gt; 3x ULN (see also sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Liver enzyme monitoring</u></p><p>&nbsp;</p><p>Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function test results returned to normal after discontinuation of treatment. Liver function tests should be performed prior to the initiation of treatment with JALRA in order to know the patient&rsquo;s baseline value. Liver function should be monitored during treatment with JALRA at three-month intervals during the first year and periodically thereafter. Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality(ies) return(s) to normal. Should an increase in AST or ALT of 3x ULN or greater persist, withdrawal of JALRA therapy is recommended.</p><p>&nbsp;</p><p>Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue JALRA.</p><p>&nbsp;</p><p>Following withdrawal of treatment with JALRA and LFT normalisation, treatment with JALRA should not be reinitiated.</p><p>&nbsp;</p><p><u>Cardiac failure</u></p><p>&nbsp;</p><p>A clinical trial of vildagliptin in patients with New York Heart Association (NYHA) functional class I-III showed that treatment with vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing congestive heart failure (CHF) versus placebo. Clinical experience in patients with NYHA functional class III treated with vildagliptin is still limited and results are inconclusive (see section 5.1).</p><p>&nbsp;</p><p>There is no experience of vildagliptin use in clinical trials in patients with NYHA functional class IV and therefore use is not recommended in these patients.</p><p>&nbsp;</p><p><u>Skin disorders</u></p><p>&nbsp;</p><p>Skin lesions, including blistering and ulceration have been reported in extremities of monkeys in non- clinical toxicology studies (see section 5.3). Although skin lesions were not observed at an increased incidence in clinical trials, there was limited experience in patients with diabetic skin complications. Furthermore, there have been post-marketing reports of bullous and exfoliative skin lesions. Therefore, in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.</p><p>&nbsp;</p><p><u>Acute pancreatitis</u></p><p>&nbsp;</p><p>Use of vildagliptin has been associated with a risk of developing acute pancreatitis. Patients should be informed of the characteristic symptom of acute pancreatitis.</p><p>&nbsp;</p><p>If pancreatitis is suspected, vildagliptin should be discontinued; if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.</p><p>&nbsp;</p><p><u>Hypoglycaemia</u></p><p>&nbsp;</p><p>Sulphonylureas are known to cause hypoglycaemia. Patients receiving vildagliptin in combination with a sulphonylurea may be at risk for hypoglycaemia. Therefore, a lower dose of sulphonylurea may be considered to reduce the risk of hypoglycaemia.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>This medicine contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vildagliptin has a low potential for interactions with co-administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes.</p><p>&nbsp;</p><p><u>Combination with pioglitazone, metformin and glyburide</u></p><p>&nbsp;</p><p>Results from studies conducted with these oral antidiabetics have shown no clinically relevant pharmacokinetic interactions.</p><p>&nbsp;</p><p><u>Digoxin (Pgp substrate), warfarin (CYP2C9 substrate)</u></p><p>&nbsp;</p><p>Clinical studies performed with healthy subjects have shown no clinically relevant pharmacokinetic interactions. However, this has not been established in the target population.</p><p>&nbsp;</p><p><u>Combination with amlodipine, ramipril, valsartan or simvastatin</u></p><p>&nbsp;</p><p>Drug-drug interaction studies in healthy subjects were conducted with amlodipine, ramipril, valsartan and simvastatin. In these studies, no clinically relevant pharmacokinetic interactions were observed after co- administration with vildagliptin.</p><p>&nbsp;</p><p><u>Combination with ACE-inhibitors</u></p><p>&nbsp;</p><p>There may be an increased risk of angioedema in patients concomitantly taking ACE-inhibitors.(see section 4.8).</p><p>&nbsp;</p><p>As with other oral antidiabetic medicinal products the hypoglycaemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate data from the use of vildagliptin in pregnant women. Studies in animals have shown reproductive toxicity at high doses (see section 5.3). The potential risk for humans is unknown. Due to lack of human data, JALRA should not be used during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether vildagliptin is excreted in human milk. Animal studies have shown excretion of vildagliptin in milk. JALRA should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No studies on the effect on human fertility have been conducted for JALRA (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Patients<br />who experience dizziness as an adverse reaction should avoid driving vehicles or using<br />machines.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  margin-left:1in;margin-top:12.65pt;width:467.5pt;height:38.05pt;z-index:-251658240;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' fillcolor="yellow" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:2.55pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:justify'>Safety
     data were obtained from a total of 5,451 patients exposed to vildagliptin
     at a daily dose of 100 mg (50<span style='letter-spacing:-.45pt'> </span>mg<span
     style='letter-spacing:-.25pt'> </span>twice<span style='letter-spacing:
     -.3pt'> </span>daily)<span style='letter-spacing:-.15pt'> </span>in<span
     style='letter-spacing:-.45pt'> </span>randomised<span style='letter-spacing:
     -.2pt'> </span>double-blind<span style='letter-spacing:-.15pt'> </span>placebo-controlled<span
     style='letter-spacing:-.4pt'> </span>trials<span style='letter-spacing:
     -.15pt'> </span>of<span style='letter-spacing:-.3pt'> </span>at<span
     style='letter-spacing:-.25pt'> </span>least<span style='letter-spacing:
     -.05pt'> </span>12<span style='letter-spacing:-.25pt'> </span>weeks<span
     style='letter-spacing:-.2pt'> </span>duration.<span style='letter-spacing:
     -.15pt'> </span>Of these patients, 4,622 patients received vildagliptin as
     monotherapy and 829 patients received<span style='letter-spacing:-1.1pt'> </span>placebo.<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="626" height="54" alt="Text Box: Safety data were obtained from a total of 5,451 patients exposed to vildagliptin at a daily dose of 100 mg (50 mg twice daily) in randomised double-blind placebo-controlled trials of at least 12 weeks duration. Of these patients, 4,622 patients received vildagliptin as monotherapy and 829 patients received placebo." src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>The majority of adverse reactions in these trials were mild and transient, not requiring treatment discontinuations. No association was found between adverse reactions and age, ethnicity, duration of exposure or daily dose. Hypoglycaemia has been reported in patients receiving vildagliptin concomitantly with sulphonylurea and insulin. The risk of acute pancreatitis has been reported with the use of vildagliptin (see section 4.4).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions reported in patients who received JALRA in double-blind studies as monotherapy and add-on therapies are listed below for each indication by system organ class and absolute frequency. Frequencies are defined as very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1 000 to</p><p>&lt;1/100), rare (&ge;1/10 000 to &lt;1/1 000), very rare (&lt;1/10 000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:rect
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:1in;margin-top:4.65pt;width:461.4pt;height:12.6pt;z-index:-252663808;
 mso-position-horizontal-relative:page' fillcolor="yellow" stroked="f">
 <w:wrap anchorx="page"/>
</v:rect><![endif]--><img width="615" height="17" src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />Table 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions reported in patients who received vildagliptin as monotherapy or as add-on therapy in controlled clinical studies and in post-marketing experience</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class - adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastro-oesophageal reflux disease</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain, including upper</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>Not known*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pruritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dermatitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Exfoliative and bullous skin lesions, including bullous pemphigoid</p></td><td style="vertical-align:top"><p>Not known*</p></td></tr><tr><td style="vertical-align:top"><p>Cutaneous vasculitis</p></td><td style="vertical-align:top"><p>Not known*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Abnormal liver function tests</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Weight increase</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on post-marketing experience.</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p><!--[if gte vml 1]><v:rect id="_x0000_s1028"
 style='position:absolute;left:0;text-align:left;margin-left:198.8pt;
 margin-top:36.85pt;width:2.75pt;height:.5pt;z-index:251660288;
 mso-position-horizontal-relative:page' fillcolor="black" stroked="f">
 <w:wrap anchorx="page"/>
</v:rect><![endif]--><img width="3" height="1" src="file:///C:/Users/asus/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" />Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function returned to normal after discontinuation of treatment. In data from controlled monotherapy and add-on therapy trials of up to</p><p>24 weeks in duration, the incidence of ALT or AST elevations &ge; 3x ULN (classified as present on at least 2 consecutive measurements or at the final on-treatment visit) was 0.2%, 0.3% and 0.2% for vildagliptin 50 mg once daily, vildagliptin 50 mg twice daily and all comparators, respectively. These elevations in transaminases were generally asymptomatic, non-progressive in nature and not associated with cholestasis or jaundice.</p><p>&nbsp;</p><p><em><u>Angioedema</u></em></p><p>Rare cases of angioedema have been reported on vildagliptin at a similar rate to controls. A greater proportion of cases were reported when vildagliptin was administered in combination with an angiotensin converting enzyme inhibitor (ACE-Inhibitor). The majority of events were mild in severity and resolved with ongoing vildagliptin treatment.</p><p>&nbsp;</p><p><em><u>Hypoglycaemia</u></em></p><p>Hypoglycaemia was uncommon when vildagliptin (0.4%) was used as monotherapy in comparative controlled monotherapy studies with an active comparator or placebo (0.2%). No severe or serious events of hypoglycaemia were reported. When used as add-on to metformin, hypoglycaemia occurred in 1% of vildagliptin-treated patients and in 0.4% of placebo-treated patients. When pioglitazone was added, hypoglycaemia occurred in 0.6% of vildagliptin-treated patients and in 1.9% of placebo-treated patients. When sulphonylurea was added, hypoglycaemia occurred in 1.2% of vildagliptin treated patients and in 0.6% of placebo-treated patients. When sulphonylurea and metformin were added, hypoglycaemia occurred in 5.1% of vildagliptin treated patients and in 1.9% of placebo treated patients. In patients taking vildagliptin in combination with insulin, the incidence of hypoglycaemia was 14% for vildagliptin and 16% for placebo.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o&nbsp; SFDA call center: 19999</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information regarding overdose with vildagliptin is limited. <u>Symptoms</u></p><p>Information on the likely symptoms of overdose was taken from a rising dose tolerability study in healthy subjects given JALRA for 10 days. At 400 mg, there were three cases of muscle pain, and individual cases of mild and transient paraesthesia, fever, oedema and a transient increase in lipase levels. At 600 mg, one subject experienced oedema of the feet and hands, and increases in creatine phosphokinase (CPK), aspartate aminotransferase (AST), C-reactive protein (CRP) and myoglobin levels. Three other subjects experienced oedema of the feet, with paraesthesia in two cases. All symptoms and laboratory abnormalities resolved without treatment after discontinuation of the study medicinal product.</p><p>&nbsp;</p><p><u>Management</u></p><p>&nbsp;</p><p>In the event of an overdose, supportive management is recommended. Vildagliptin cannot be removed by haemodialysis. However, the major hydrolysis metabolite (LAY 151) can be removed by haemodialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code: A10BH02</p><p>&nbsp;</p><p>Vildagliptin, a member of the islet enhancer class, is a potent and selective DPP-4 inhibitor. <u>Mechanism of action</u></p><p>The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. Treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta cell function including HOMA-&beta; (Homeostasis Model Assessment&ndash;&beta;), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently-sampled meal tolerance test. In non-diabetic (normal glycaemic) individuals, vildagliptin does not stimulate insulin secretion or reduce glucose levels.</p><p>&nbsp;</p><p>By increasing endogenous GLP-1 levels, vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.</p><p>&nbsp;</p><p>The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.</p><p>&nbsp;</p><p>The known effect of increased GLP-1 levels delaying gastric emptying is not observed with vildagliptin treatment.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>More than 15 000 patients with type 2 diabetes participated in double-blind placebo- or active-controlled clinical trials of up to more than 2 years&rsquo; treatment duration. In these studies, vildagliptin was administered to more than 9 000 patients at daily doses of 50 mg once daily, 50 mg twice daily or 100 mg once daily. More than 5 000 male and more than 4 000 female patients received vildagliptin 50 mg once daily or 100 mg daily. More than 1 900 patients receiving vildagliptin 50 mg once daily or 100 mg daily were &ge; 65 years. In these trials, vildagliptin was administered as monotherapy in drug-na&iuml;ve patients with type 2 diabetes or in combination in patients not adequately controlled by other antidiabetic medicinal products.</p><p>&nbsp;</p><p>Overall, vildagliptin improved glycaemic control when given as monotherapy or when used in combination with metformin, a sulphonylurea, and a thiazolidinedione, as measured by clinically relevant reductions in HbA1c from baseline at study endpoint (see Table 2).</p><p>&nbsp;</p><p>In clinical trials, the magnitude of HbA1c reductions with vildagliptin was greater in patients with higher baseline HbA1c.</p><p>&nbsp;</p><p>In a 52-week double-blind controlled trial, vildagliptin (50 mg twice daily) reduced baseline HbA1c</p><p>by -1% compared to -1.6% for metformin (titrated to 2 g/day) statistical non-inferiority was not achieved. Patients treated with vildagliptin reported significantly lower incidences of gastrointestinal adverse reactions versus those treated with metformin.</p><p>&nbsp;</p><p>In a 24-week double-blind controlled trial, vildagliptin (50 mg twice daily) was compared to rosiglitazone (8 mg once daily). Mean reductions were -1.20% with vildagliptin and -1.48% with rosiglitazone in patients with mean baseline HbA1c of 8.7%. Patients receiving rosiglitazone experienced a mean increase in weight (+1.6 kg) while those receiving vildagliptin experienced no weight gain (-0.3 kg). The incidence of peripheral oedema was lower in the vildagliptin group than in the rosiglitazone group (2.1% vs. 4.1% respectively).</p><p>&nbsp;</p><p>In a clinical trial of 2 years&rsquo; duration, vildagliptin (50 mg twice daily) was compared to gliclazide (up to</p><p>&nbsp;</p><p>320 mg/day). After two years, mean reduction in HbA1c was -0.5% for vildagliptin and -0.6% for gliclazide, from a mean baseline HBA1c of 8.6%. Statistical non-inferiority was not achieved. Vildagliptin&nbsp;was associated with fewer hypoglycaemic events (0.7%) than gliclazide (1.7%).</p><p>&nbsp;</p><p>In a 24-week trial, vildagliptin (50 mg twice daily) was compared to pioglitazone (30 mg once daily) in patients inadequately controlled with metformin (mean daily dose: 2020 mg). Mean reductions from baseline HbA1c of 8.4% were -0.9% with vildagliptin added to metformin and -1.0% with pioglitazone added to metformin. A mean weight gain of +1.9 kg was observed in patients receiving pioglitazone added to metformin compared to +0.3 kg in those receiving vildagliptin added to metformin.</p><p>&nbsp;</p><p>In a clinical trial of 2 years&rsquo; duration, vildagliptin (50 mg twice daily) was compared to glimepiride (up to 6 mg/day &ndash; mean dose at 2 years: 4.6 mg) in patients treated with metformin (mean daily dose: 1894 mg). After 1 year mean reductions in HbA1c were -0.4% with vildagliptin added to metformin and -0.5% with glimepiride added to metformin, from a mean baseline HbA1c of 7.3%. Body weight change with vildagliptin was -0.2 kg vs +1.6 kg with glimepiride. The incidence of hypoglycaemia was significantly lower in the vildagliptin group (1.7%) than in the glimepiride group (16.2%). At study endpoint (2 years), the HbA1c was similar to baseline values in both treatment groups and the body weight changes and hypoglycaemia differences were maintained.</p><p>&nbsp;</p><p>In a 52-week trial, vildagliptin (50 mg twice daily) was compared to gliclazide (mean daily dose:</p><p>229.5 mg) in patients inadequately controlled with metformin (metformin dose at baseline 1928 mg/day). After 1 year, mean reductions in HbA1c were -0.81% with vildagliptin added to metformin (mean baseline HbA1c 8.4%) and -0.85% with gliclazide added to metformin (mean baseline HbA1c 8.5%); statistical non-&nbsp;inferiority was achieved (95% CI -0.11 &ndash; 0.20). Body weight change with vildagliptin was +0.1 kg compared to a weight gain of +1.4 kg with gliclazide.</p><p>&nbsp;</p><p>In a 24-week trial the efficacy of the fixed dose combination of vildagliptin and metformin (gradually titrated to a dose of 50 mg/500 mg twice daily or 50 mg/1000 mg twice daily) as initial therapy in drug- na&iuml;ve patients was evaluated. Vildagliptin/metformin 50 mg/1000 mg twice daily reduced HbA1c</p><p>by -1.82%, vildagliptin/metformin 50 mg/500 mg twice daily by -1.61%, metformin 1000 mg twice daily by -1.36% and vildagliptin 50 mg twice daily by -1.09% from a mean baseline HbA1c of 8.6%. The decrease in HbA1c observed in patients with a baseline &ge;10.0% was greater.</p><p>&nbsp;</p><p>A 24-week, multi-centre, randomised, double-blind, placebo-controlled trial was conducted to evaluate the treatment effect of vildagliptin 50 mg once daily compared to placebo in 515 patients with type 2 diabetes and moderate renal impairment (N=294) or severe renal impairment (N=221). 68.8% and 80.5% of the patients with moderate and severe renal impairment respectively were treated with insulin (mean daily dose of 56 units and 51.6 units respectively) at baseline. In patients with moderate renal impairment vildagliptin significantly decreased HbA1c compared with placebo (difference of -0.53%) from a mean baseline of 7.9%. In patients with severe renal impairment, vildagliptin significantly decreased HbA1c compared with placebo (difference of -0.56%) from a mean baseline of 7.7%.</p><p>&nbsp;</p><p>A 24-week randomised, double-blind, placebo-controlled trial was conducted in 318 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with metformin (&ge;1500 mg daily) and glimepiride (&ge;4 mg daily). Vildagliptin in combination with metformin and glimepiride significantly decreased HbA1c compared with placebo.The placebo-adjusted mean reduction from a mean baseline HbA1c of 8.8% was -0.76%.</p><p>&nbsp;</p><p>A 24-week randomised, double-blind, placebo-controlled trial was conducted in 449 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with a stable dose of basal or premixed insulin (mean daily dose 41 units), with concomitant use of metformin (N=276) or without</p><p>&nbsp;</p><p>concomitant metformin (N=173). Vildagliptin in combination with insulin significantly decreased HbA1c compared with placebo. In the overall population, the placebo-adjusted mean reduction from a mean baseline HbA1c 8.8% was -0.72%. In the subgroups treated with insulin with or without concomitant metformin the placebo-adjusted mean reduction in HbA1c was -0.63% and -0.84%, respectively. The incidence of hypoglycaemia in the overall population was 8.4% and 7.2% in the vildagliptin and placebo groups, respectively. Patients receiving vildagliptin experienced no weight gain (+0.2 kg) while those receiving placebo experienced weight reduction (-0.7 kg).</p><p>&nbsp;</p><p>In another 24-week study in patients with more advanced type 2 diabetes not adequately controlled on insulin (short and longer acting, average insulin dose 80 IU/day), the mean reduction in HbA1c when vildagliptin (50 mg twice daily) was added to insulin was statistically significantly greater than with placebo plus insulin (0.5% vs. 0.2%). The incidence of hypoglycaemia was lower in the vildagliptin group than in the placebo group (22.9% vs. 29.6%).</p><p>&nbsp;</p><p>A 52-week multi-centre, randomised, double-blind trial was conducted in patients with type 2 diabetes and congestive heart failure (NYHA functional class I-III) to evaluate the effect of vildagliptin 50 mg twice daily (N=128) compared to placebo (N=126) on left-ventricular ejection fraction (LVEF).</p><p>Vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing CHF. Adjudicated cardiovascular events were balanced overall. There were more cardiac events in vildagliptin treated patients with NYHA class III heart failure compared to placebo. However, there were imbalances in baseline cardiovascular risk favouring placebo and the number of events was low, precluding firm conclusions. Vildagliptin significantly decreased HbA1c compared with placebo (difference of 0.6%) from a mean baseline of 7.8% at week 16. In the subgroup with NYHA class III, the decrease in HbA1c compared to placebo was lower (difference 0.3%) but this conclusion is limited by the small number of patients (n=44). The incidence of hypoglycaemia in the overall population was 4.7% and 5.6% in the vildagliptin and placebo groups, respectively.</p><p>&nbsp;</p><p>A five-year multi-centre, randomised, double-blind study (VERIFY) was conducted in patients with type 2 diabetes to evaluate the effect of an early combination therapy with vildagliptin and metformin (N</p><p>= 998) against standard-of-care initial metformin monotherapy followed by combination with vildagliptin (sequential treatment group) (N = 1 003) in newly diagnosed patients with type 2 diabetes. The combination regimen of vildagliptin 50 mg twice daily plus metformin resulted in a statistically and clinically significant relative reduction in hazard for &ldquo;time to confirmed initial treatment failure&rdquo; (HbA1c value &ge;7%) vs metformin monotherapy in treatment-na&iuml;ve patients with type 2 diabetes over the 5-year study duration (HR [95%CI]: 0.51 [0.45, 0.58]; p&lt;0.001). The incidence of initial treatment failure (HbA1c value &ge;7%) was 429 (43.6%) patients in the combination treatment group and</p><p>614 (62.1%) patients in the sequential treatment group.</p><p>&nbsp;</p><p><em><u>Cardiovascular risk</u></em></p><p>A meta-analysis of independently and prospectively adjudicated cardiovascular events from 37 phase III and IV monotherapy and combination therapy clinical studies of up to more than 2 years duration (mean exposure 50 weeks for vildagliptin and 49 weeks for comparators) was performed and showed that vildagliptin treatment was not associated with an increase in cardiovascular risk versus comparators. The composite endpoint of adjudicated major adverse cardiovascular events (MACE) including acute myocardial infarction, stroke or cardiovascular death was similar for vildagliptin versus combined active and placebo comparators [Mantel&ndash;Haenszel risk ratio (M-H RR) 0.82 (95% CI 0.61-1.11)]. A MACE occurred in 83 out of 9 599 (0.86%) vildagliptin-treated patients and in 85 out of 7 102 (1.20%) comparator-treated patients. Assessment of each individual MACE component showed no increased risk (similar M-H RR). Confirmed heart failure (HF) events defined as HF requiring hospitalisation or new onset of HF were reported in 41 (0.43%) vildagliptin-treated patients and 32 (0.45%) comparator-treated patients with M-H RR 1.08 (95% CI 0.68-1.70).</p><p>&nbsp;</p><p>Table 2Key efficacy results of vildagliptin in placebo-controlled monotherapy trials and in add-on combination therapy trials (primary efficacy ITT population)</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Monotherapy placebo controlled studies</strong></p></td><td style="vertical-align:top"><p><strong>Mean baseline HbA</strong><strong>1c (%)</strong></p></td><td style="vertical-align:top"><p><strong>Mean change from baseline in</strong></p></td><td style="vertical-align:top"><p><strong>Placebo-corrected mean change in</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Study 2301: Vildagliptin 50 mg</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>8.6</p></td><td style="vertical-align:top"><p><strong>HbA</strong><strong>1c (%) at week 24</strong></p><p>-0.8</p></td><td style="vertical-align:top"><p><strong>HbA</strong><strong>1c (%) at week 24 (95% CI)</strong></p><p>-0.5* (-0.8, -0.1)</p></td></tr><tr><td style="vertical-align:top"><p>twice daily (N=90)</p><p>Study 2384: Vildagliptin 50 mg</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>8.4</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-0.7</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-0.7* (-1.1, -0.4)</p></td></tr><tr><td style="vertical-align:top"><p>twice daily (N=79)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>* p&lt; 0.05 for comp</p></td><td style="vertical-align:top"><p>arison versus placebo</p></td></tr><tr><td style="vertical-align:top"><p><strong>Add-on </strong>/ <strong>Combination studies</strong></p><p>Vildagliptin 50 mg twice daily +</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>8.4</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-0.9</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-1.1* (-1.4, -0.8)</p></td></tr><tr><td style="vertical-align:top"><p>metformin (N=143) Vildagliptin 50 mg daily +</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>8.5</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-0.6</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-0.6* (-0.9, -0.4)</p></td></tr><tr><td style="vertical-align:top"><p>glimepiride (N=132) Vildagliptin 50 mg twice daily +</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>8.7</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-1.0</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-0.7* (-0.9, -0.4)</p></td></tr><tr><td style="vertical-align:top"><p>pioglitazone (N=136) Vildagliptin 50 mg twice daily +</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>8.8</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-1.0</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-0.8* (-1.0, -0.5)</p></td></tr><tr><td style="vertical-align:top"><p>metformin + glimepiride (N=152)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>* p&lt; 0.05 for comp</p><p>+ co</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>arison versus placebo</p><p>mparator</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with vildagliptin in all subsets of the paediatric population with type 2 diabetes mellitus (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Following oral administration in the fasting state, vildagliptin is rapidly absorbed, with peak plasma concentrations observed at 1.7 hours. Food slightly delays the time to peak plasma concentration to</p><p>2.5 hours, but does not alter the overall exposure (AUC). Administration of vildagliptin with food resulted in a decreased Cmax (19%). However, the magnitude of change is not clinically significant, so that&nbsp;JALRA can be given with or without food. The absolute bioavailability is 85%.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The plasma protein binding of vildagliptin is low (9.3%) and vildagliptin distributes equally between plasma and red blood cells. The mean volume of distribution of vildagliptin at steady-state after intravenous administration (Vss) is 71 litres, suggesting extravascular distribution.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Metabolism is the major elimination pathway for vildagliptin in humans, accounting for 69% of the dose. The major metabolite (LAY 151) is pharmacologically inactive and is the hydrolysis product of the cyano</p><p>&nbsp;</p><p>moiety, accounting for 57% of the dose, followed by the glucuronide (BQS867) and the amide hydrolysis products (4% of dose). In vitro data in human kidney microsomes suggest that the kidney may be one of the major organs contributing to the hydrolysis of vildagliptin to its major inactive metabolite, LAY151. DPP-4 contributes partially to the hydrolysis of vildagliptin based on an <em>in vivo </em>study using DPP-4 deficient rats. Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent.</p><p>Accordingly, the metabolic clearance of vildagliptin is not anticipated to be affected by co-medications that are CYP 450 inhibitors and/or inducers. <em>In vitro </em>studies demonstrated that vildagliptin does not inhibit/induce CYP 450 enzymes. Therefore, vildagliptin is not likely to affect metabolic clearance of co- medications metabolised by CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 or CYP 3A4/5.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Following oral administration of [<sup>14</sup>C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose is recovered in the faeces. Renal excretion of the unchanged vildagliptin accounted for 23% of the dose after oral administration. After intravenous administration to healthy subjects, the total plasma and renal clearances of vildagliptin are 41 and 13 l/h, respectively. The mean elimination half-life after intravenous administration is approximately 2 hours. The elimination half-life after oral administration is approximately 3 hours.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>The Cmax for vildagliptin and the area under the plasma concentrations versus time curves (AUC) increased in an approximately dose proportional manner over the therapeutic dose range.</p><p>&nbsp;</p><p><u>Characteristics in specific groups of patients</u></p><p>&nbsp;</p><p><em><u>Gender</u></em></p><p>No clinically relevant differences in the pharmacokinetics of vildagliptin were observed between male and female healthy subjects within a wide range of age and body mass index (BMI). DPP-4 inhibition by vildagliptin is not affected by gender.</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>In healthy elderly subjects (&ge; 70 years), the overall exposure of vildagliptin (100 mg once daily) was increased by 32%, with an 18% increase in peak plasma concentration as compared to young healthy subjects (18-40 years). These changes are, however, not considered to be clinically relevant. DPP-4 inhibition by vildagliptin is not affected by age.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>The effect of impaired hepatic function on the pharmacokinetics of vildagliptin was studied in patients with mild, moderate and severe hepatic impairment based on the Child-Pugh scores (ranging from 6 for mild to 12 for severe) in comparison with healthy subjects. The exposure to vildagliptin after a single dose in patients with mild and moderate hepatic impairment was decreased (20% and 8%, respectively), while the exposure to vildagliptin for patients with severe impairment was increased by 22%. The maximum change (increase or decrease) in the exposure to vildagliptin is ~30%, which is not considered to be clinically relevant. There was no correlation between the severity of the hepatic disease and changes in the exposure to vildagliptin.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>A multiple-dose, open-label trial was conducted to evaluate the pharmacokinetics of the lower therapeutic dose of vildagliptin (50 mg once daily) in patients with varying degrees of chronic renal impairment</p><p>&nbsp;</p><p>defined by creatinine clearance (mild: 50 to &lt;80 ml/min, moderate: 30 to &lt;50 ml/min and severe:</p><p>&lt;30 ml/min) compared to normal healthy control subjects.</p><p>&nbsp;</p><p>Vildagliptin AUC increased on average 1.4, 1.7 and 2-fold in patients with mild, moderate and severe renal impairment, respectively, compared to normal healthy subjects. AUC of the metabolites LAY151 and BQS867 increased on average about 1.5, 3 and 7-fold in patients with mild, moderate and severe renal impairment, respectively. Limited data from patients with end stage renal disease (ESRD) indicate that vildagliptin exposure is similar to that in patients with severe renal impairment. LAY151 concentrations were approximately 2-3-fold higher than in patients with severe renal impairment.</p><p>&nbsp;</p><p>Vildagliptin was removed by haemodialysis to a limited extent (3% over a 3-4 hour haemodialysis session starting 4 hours post dose).</p><p>&nbsp;</p><p><em><u>Ethnic group</u></em></p><p>Limited data suggest that race does not have any major influence on vildagliptin pharmacokinetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intra-cardiac impulse conduction delays were observed in dogs with a no-effect dose of 15 mg/kg (7-fold human exposure based on Cmax).</p><p>&nbsp;</p><p>Accumulation of foamy alveolar macrophages in the lung was observed in rats and mice. The no-effect dose in rats was 25 mg/kg (5-fold human exposure based on AUC) and in mice 750 mg/kg (142-fold human exposure).</p><p>&nbsp;</p><p>Gastrointestinal symptoms, particularly soft faeces, mucoid faeces, diarrhoea and, at higher doses, faecal blood were observed in dogs. A no-effect level was not established.</p><p>&nbsp;</p><p>Vildagliptin was not mutagenic in conventional <em>in vitro </em>and <em>in vivo </em>tests for genotoxicity.</p><p>&nbsp;</p><p>A fertility and early embryonic development study in rats revealed no evidence of impaired fertility, reproductive performance or early embryonic development due to vildagliptin. Embryo-foetal toxicity was evaluated in rats and rabbits. An increased incidence of wavy ribs was observed in rats in association with reduced maternal body weight parameters, with a no-effect dose of 75 mg/kg (10-fold human exposure). In rabbits, decreased foetal weight and skeletal variations indicative of developmental delays were noted only in the presence of severe maternal toxicity, with a no-effect dose of 50 mg/kg (9-fold human exposure). A pre- and postnatal development study was performed in rats. Findings were only observed in association with maternal toxicity at &ge; 150 mg/kg and included a transient decrease in body weight and reduced motor activity in the F1 generation.</p><p>&nbsp;</p><p>A two-year carcinogenicity study was conducted in rats at oral doses up to 900 mg/kg (approximately 200 times human exposure at the maximum recommended dose). No increases in tumour incidence attributable to vildagliptin were observed. Another two-year carcinogenicity study was conducted in mice at oral doses up to 1000 mg/kg. An increased incidence of mammary adenocarcinomas and haemangiosarcomas was observed with a no-effect dose of 500 mg/kg (59-fold human exposure) and 100 mg/kg (16-fold human exposure), respectively. The increased incidence of these tumours in mice is considered not to represent a significant risk to humans based on the lack of genotoxicity of vildagliptin and its principal metabolite, the occurrence of tumours only in one species and the high systemic exposure ratios at which tumours were observed.</p><p>&nbsp;</p><p>In a 13-week toxicology study in cynomolgus monkeys, skin lesions have been recorded at doses</p><p>&nbsp;</p><p>&ge; 5 mg/kg/day. These were consistently located on the extremities (hands, feet, ears and tail). At</p><p>5 mg/kg/day (approximately equivalent to human AUC exposure at the 100 mg dose), only blisters were observed. They were reversible despite continued treatment and were not associated with histopathological abnormalities. Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were noted at doses &ge; 20 mg/kg/day (approximately 3 times human AUC exposure at the 100 mg dose). Necrotic lesions of the tail were observed at &ge; 80 mg/kg/day. Skin lesions were not reversible in the monkeys treated at 160 mg/kg/day during a 4-week recovery period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose, anhydrous<br />Cellulose, microcrystalline<br />Sodium starch glycolate (type A)<br />Magnesium stearate<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from moisture.<br />Do not Store above 30 &deg;C .<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/Aluminium (PA/Al/PVC//Al) blister<br />Available in packs containing 28 and 56 tablets<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical Co., Ltd.
Jeddah – Saudi Arabia
Under License from Novartis Pharma AG, Switzerland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October / 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>